World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
28605
World Ranking
12234
National Ranking
383

Overview

Christian Recher is affiliated with the Federal University of Toulouse Midi-Pyrénées in France. Their research primarily focuses on medicine, with significant contributions in biochemistry, genetics, and molecular biology. Within these fields, they specialize notably in hematology and molecular biology, with further engagement in genetics, oncology, and public health, environmental, and occupational health.

The scientist's work addresses various topics, including:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Acute Lymphoblastic Leukemia Research
  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments

Christian Recher has published extensively in several key scientific venues. The most frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • Journal of Clinical Oncology
  • Leukemia

Their recent research papers cover a range of subjects mainly related to acute myeloid leukemia and related treatments. Noteworthy papers include:

  • "Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia," 2022, New England Journal of Medicine
  • "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia," 2020, Blood
  • "Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia," 2022, New England Journal of Medicine
  • "Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)," 2021, Journal of Clinical Oncology
  • "Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine," 2021, Journal of Clinical Oncology

Collaboration plays a notable role in their research activities. Frequent coauthors include:

  • Arnaud Pigneux
  • Sarah Bertoli
  • Éric Delabesse
  • Pierre-Yves Dumas
  • Pau Montesinos

Christian Recher's work contributes to understanding and improving therapies related to hematological malignancies, especially focusing on molecular and clinical aspects within acute and chronic myeloid leukemias, among other areas.

Best Publications

  • International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

    Hervé Dombret;John F. Seymour;Aleksandra Butrym;Agnieszka Wierzbowska

  • Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

    Alexander E. Perl;Giovanni Martinelli;Jorge E. Cortes;Andreas Neubauer

  • Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials

    Robert Kerrin Hills;Sylvie Castaigne;Frederick R. Appelbaum;Jacques Delaunay

  • Chemotherapy Resistant Human Acute Myeloid Leukemia Cells are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

    Thomas Farge;Thomas Farge;Estelle saland;Estelle saland;Fabienne de Toni;Fabienne de Toni;Nesrine Aroua;Nesrine Aroua

  • High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

    Arnaud Jaccard;Philippe Moreau;Véronique Leblond;Xavier Leleu

  • Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

    Thomas Prébet;Steven D. Gore;Benjamin Esterni;Claude Gardin

  • Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support.

    E Azoulay;C Alberti;C Bornstain;G Leleu

  • Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

    Jean-Emmanuel Sarry;Kathleen Murphy;Robin Perry;Patricia V. Sanchez

  • Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

    Raphael Itzykson;Sylvain Thépot;Bruno Quesnel;Francois Dreyfus

  • Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

    Céline Berthon;Emmanuel Raffoux;Xavier Thomas;Norbert Vey

  • Antileukemic activity of rapamycin in acute myeloid leukemia.

    Christian Récher;Odile Beyne-Rauzy;Cécile Demur;Gaëtan Chicanne

  • Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

    Eric Jourdan;Nicolas Boissel;Sylvie Chevret;Eric Delabesse

  • Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

    Ruxanda Moschoi;Ruxanda Moschoi;Véronique Imbert;Véronique Imbert;Marielle Nebout;Marielle Nebout;Johanna Chiche;Johanna Chiche

  • Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

    Nathalie Jacque;Anne Marie Ronchetti;Clément Larrue;Clément Larrue;Godelieve Meunier

  • Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

    Lionel Adès;Lionel Adès;Agnes Guerci;Emmanuel Raffoux;Miguel Sanz

  • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

    Christian Récher;Bertrand Coiffier;Corinne Haioun;Thierry Jo Molina

  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

    Geoffrey L. Uy;Ibrahim Aldoss;Matthew C. Foster;Peter H. Sayre

  • Expression and prognostic significance of survivin in de novo acute myeloid leukaemia

    Colette Adida;Christian Recher;Emmanuel Raffoux;Marie‐Thérèse Daniel

  • Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab

    P. Feugier;J. M. Virion;H. Tilly;C. Haioun

  • MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

    Christiane Copie-Bergman;Christiane Copie-Bergman;Peggy Cuillière-Dartigues;Maryse Baia;Josette Briere

Frequent Co-Authors

Eric Delabesse
Eric Delabesse Cancer Research Center of Toulouse
Hervé Dombret
Hervé Dombret Université Paris Cité
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Emmanuel Raffoux
Emmanuel Raffoux Hôpital Saint-Louis
Norbert Ifrah
Norbert Ifrah Grenoble Alpes University
Stéphane de Botton
Stéphane de Botton Institut Gustave Roussy
Claude Preudhomme
Claude Preudhomme University of Lille
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Sylvie Chevret
Sylvie Chevret Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine, exploring online degrees and alternative healthcare career pathways can open up more flexible and affordable options. Many prospective medical professionals choose related fields that offer strong job opportunities, specialized skills, and the potential for career advancement.

One popular option is pursuing the cheapest master's in healthcare administration, ideal for those aiming for leadership roles in hospitals and clinics. For nurses wanting to reach the highest clinical positions, the most affordable dnp programs provide a cost-effective path to a Doctor of Nursing Practice degree.

Pharmacy is another in-demand field, and flexible learning is available through online pharmacy programs that deliver advanced training without relocating. Those interested in healthcare data or informatics may benefit from a bachelor of health information management online to prepare for roles in medical records, compliance, and technology.

By considering these accredited online programs, you can diversify your options and build a rewarding career in the expanding healthcare sector.

Best Scientists Citing Christian Recher

Trending Scientists